Press release
Market Growth of Vesicular Stomatitis (VS) Therapeutics to Remain Sluggish through 2017-2025
A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/16642
The disease is contagious and spread via insect vectors, animal contact, and exposure to saliva or fluids. It is endemic in Southwestern and Western United States as the region have experienced a number of vesicular stomatitis outbreaks in the past decade. This results in economic loss to livestock producers and affects the international trade of animals and animal products. Effective management of animals helps the disease transmission in the herd.
Humans living in enzootic areas such as the animal handlers also have a high chances of infection and lead to the influenza like symptoms. The morbidity rate for the disease in animals is also highly variable, and ranges from 5% to 90%.
Only symptomatic treatment with some precautionary measure are available for the disease which consists of supportive care including the prevention or treatment of secondary infections.
Vesicular Stomatitis (VS) Therapeutics Market: Drivers & Restraints
Human population growth, income growth and urbanization increases the demand of livestock products and thus the livestock population which however also increases the therapeutic products demand for animals and thus fuels the vesicular stomatitis therapeutics market. Recently in 2015, Vesicular stomatitis outbreak affected around 800 premises in 8 US states. These outbreaks are also increasing the demand for the therapeutics. Market for the vaccination of vesicular stomatitis is also high because of the unavailability of antiviral treatments. Government efforts in this direction are also the driving factors for the growth of the market. Although cases occur throughout year but occurrence of outbreaks in the US after long intervals of 5-10 years limits the therapeutic market to grow. Less research activities and product launches in this area restricts its market to expand.
Vesicular Stomatitis (VS) Therapeutics Market: Segmentation
By Treatment Type:
Symptomatic Medications
Anti-inflammatory medications
Antibiotics & Antipyretics
Antiseptic cleansing solutions
Vaccination
By Distribution Channels:
Veterinary Hospitals
Veterinary Clinics
Retail Pharmacies
By Geography
North America
Europe
Latin America
Asia-Pacific
Middle East and Africa
No specific treatment is available for the vesicular stomatitis which also creates an opportunity for the bio-pharmaceutical manufacturers to develop new and innovative drugs as to prevent the livestock economic loss. The therapeutic market is region specific as well as seasonal as the disease runs mostly from spring to fall, thus natural seasonal outbreaks are the factor for therapeutics market. Non-availability of anti-viral drugs in the market doesn’t meet the demand of the treatment.
A geographic condition regarding the Vesicular Stomatitis (VS) Therapeutics Market, it has been segmented into five key regions: North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa. Because of regional prevalence of the disease, its therapeutic market is dominant in North America followed by Latin America. As the disease is prevalent in the tropical climates, the therapeutic market also finds an opportunity in the Asia-Pacific and African regions but very less than the western hemisphere.
To view TOC of this report is available upon request @ https://www.persistencemarketresearch.com/toc/16642
Some of the players in the vesicular stomatitis therapeutic market includes Zoetis, Vedco Inc., Boehringer Ingelheim, Merck & Co., Bayer, Elanco, Ceva Santé Animale, Vibrac S.A., Vetoquinol S.A. and others.
About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Market Growth of Vesicular Stomatitis (VS) Therapeutics to Remain Sluggish through 2017-2025 here
News-ID: 726441 • Views: …
More Releases from Persistence Market Research
Human Immunodeficiency Virus Therapeutics Market Surges with Novel Drug Developm …
The global Human Immunodeficiency Virus (HIV) therapeutics market is experiencing a steady growth trajectory, driven by ongoing advancements in drug development, increasing awareness, and expanding access to treatments. The market size for HIV therapeutics was valued at USD 10.65 billion in 2023 and is projected to reach USD 12.12 billion by 2030, growing at a compound annual growth rate (CAGR) of 1.9% from 2023 to 2030. This growth is attributed…
Anti-venom Market to Expand at 3.5% CAGR Through 2032, Finds Persistence Market …
The global anti-venom market is poised for significant growth over the next decade. Valued at approximately US$2.6 billion in 2025, the market is projected to reach US$3.3 billion by 2032, registering a compound annual growth rate (CAGR) of 3.5% from 2025 to 2032. This growth is primarily driven by the rising incidence of venomous snakebites, especially in rural and tropical areas, the increasing demand for multi-species anti-venoms, technological advancements in…
Kidney Dialysis Equipment Market to Reach US$30.2 Bn by 2032, Driven by Home-Bas …
The kidney dialysis equipment market plays a vital role in enabling effective renal replacement therapy for patients suffering from chronic kidney disease (CKD) and end-stage renal disease (ESRD). These systems are designed to perform blood purification by removing waste, toxins, and excess fluids when kidney function is impaired. The growing prevalence of kidney-related disorders, coupled with the rising geriatric population and increasing adoption of home-based dialysis, is fueling market demand…
Human Augmentation Market Expected to Surge at 21.2% CAGR Through 2032 - Persist …
The human augmentation market plays a pivotal role in enhancing human capabilities, performance, and quality of life. Human augmentation technologies encompass wearable devices, implantable devices, exoskeletons, neural interfaces, and bio-enhancement solutions that improve physical, cognitive, and sensory functions. These technologies are extensively applied in healthcare, defense, industrial operations, sports, and personal wellness, enabling humans to overcome physical limitations, enhance productivity, and improve safety. According to the latest study, the global…
More Releases for Vesicular
Evolving Market Trends In The Vesicular Monoamine Transporter 2 (VMAT2) Inhibito …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
What Is the Expected Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Size During the Forecast Period?
The market for the vesicular monoamine transporter 2 (VMAT2) inhibitor has experienced swift expansion in the recent past. The market, which was valued at $1.13 billion in 2024, is slated to reach $1.25 billion in 2025,…
Harnessing Innovation Against Vesicular Stomatitis: A New Era in Therapeutics Ma …
Vesicular Stomatitis (VS) is an acute viral disease affecting livestock, primarily cattle, horses, and swine, with sporadic outbreaks that disrupt animal health, agricultural productivity, and international trade. As biosecurity measures intensify and animal welfare becomes paramount, the market for VS therapeutics is gaining strategic importance. From antiviral compounds and immunomodulators to supportive care solutions and novel vaccine platforms, stakeholders in veterinary pharmaceuticals are charting a path toward more effective prevention…
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Market Set to Reach $1.85 Bi …
What market dynamics are playing a key role in accelerating the growth of the vesicular monoamine transporter 2 (vmat2) inhibitor market?
The rising prevalence of Parkinson's disease is expected to drive the growth of the vesicular monoamine transporter 2 (VMAT2) inhibitor market in the coming years. Parkinson's disease is a progressive neurological disorder that affects movement due to the loss of dopamine-producing cells in the brain. The rising prevalence of Parkinson's…
Technology Advancing at a Rapid Pace to Drive the Vesicular Stomatitis Therapeut …
Vesicular Stomatitis is a viral disease affecting the livestock population such as pigs, horses, ruminants and causes vesicles, erosions and ulcers on the udder, feet and mouth. The disease is contagious and spread via insect vectors, animal contact, and exposure to saliva or fluids. It is endemic in Southwestern and Western United States as the region have experienced a number of vesicular stomatitis outbreaks in the past decade. This results…
Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market to Regist …
Vesicular monoamine transporter 2 (VMAT2) is a membrane-embedded protein that is responsible for uptake of monoamines neurotransmitters such as dopamine, serotonin, norepinephrine, and histamines into the synaptic vesicles in monoaminergic neurons. Vesicular monoamine transporter proteins 2 are expressed in the central nervous system (CNS) and plays the crucial role in the signaling process between the monoamine neurons. VMAT2 is the only transporter that carries the cytoplasmic dopamine into the vesicles.…
Vesicular Monoamine Transporter-2 Inhibitors (VMAT2 Inhibitors) Market Analysis, …
Vesicular monoamine transporter 2 (VMAT2) is a membrane-embedded protein that is responsible for uptake of monoamines neurotransmitters such as dopamine, serotonin, norepinephrine, and histamines into the synaptic vesicles in monoaminergic neurons.
View Report-
https://www.transparencymarketresearch.com/vesicular-monoamine-transporter2-inhibitors-market.html
Vesicular monoamine transporter proteins 2 are expressed in the central nervous system (CNS) and plays the crucial role in the signaling process between the monoamine neurons. VMAT2 is the only transporter that carries the cytoplasmic dopamine into the vesicles.…
